TAXYNERGY: Randomized trial of early switch from first-line docetaxel (D) to cabazitaxel (C) or vice versa with circulating tumor cell (CTC) biomarkers in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

被引：7
|
作者：
Tagawa, Scott T.
Antonarakis, Emmanuel S.
Saad, Fred
Vanhuyse, Marie
Sonpavde, Guru
North, Scott A.
Albany, Costantine
Tsao, Che-Kai
Stewart, John
Zaher, Atef
Szatrowski, Ted P.
Zhou, Wei
Galletti, Giuseppe
Worroll, Daniel
Eisenberger, Mario A.
Nanus, David M.
Giannakakou, Paraskevi
机构：
[1] Weill Cornell Med, New York, NY USA
[2] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA
[3] Univ Montreal, Hosp Ctr, Montreal, PQ, Canada
[4] Montreal Gen Hosp, Med Oncol, Montreal, PQ, Canada
[5] Univ Alabama Birmingham, Birmingham Comprehens Canc Ctr, Birmingham, AL USA
[6] Univ Alberta, Cross Canc Inst, Edmonton, AB, Canada
[7] Indiana Univ Sch Med, Indianapolis, IN 46202 USA
[8] Mt Sinai Med Ctr, New York, NY 10029 USA
[9] Sanofi, Laval, PQ, Canada
[10] Sanofi, Bridgewater, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.5007
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5007
引用
收藏
页数：2
相关论文
共 50 条
  • [1] TAXYNERGY (NCT01718353): A randomized phase II trial examining an early switch from first-line docetaxel to cabazitaxel, or cabazitaxel to docetaxel, in men with metastatic castration-resistant prostate cancer (mCRPC).
    Antonarakis, Emmanuel S.
    Giannakakou, Paraskevi
    Kirby, Brian J.
    Nicacio, Leonardo V.
    Eisenberger, Mario A.
    Nanus, David M.
    Tagawa, Scott T.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [2] Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA
    Oudard, Stephane
    Fizazi, Karim
    Sengelov, Lisa
    Daugaard, Gedske
    Saad, Fred
    Hansen, Steinbjorn
    Hjalm-Eriksson, Marie
    Jassem, Jacek
    Thiery-Vuillemin, Antoine
    Caffo, Orazio
    Castellano, Daniel
    Mainwaring, Paul N.
    Bernard, John
    Shen, Liji
    Chadjaa, Mustapha
    Sartor, Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (28) : 3189 - +
  • [3] Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naive, Metastatic, Castration-Resistant Prostate Cancer
    Antonarakis, Emmanuel S.
    Tagawa, Scott T.
    Galletti, Giuseppe
    Worroll, Daniel
    Ballman, Karla
    Vanhuyse, Marie
    Sonpavde, Guru
    North, Scott
    Albany, Costantine
    Tsao, Che-Kai
    Stewart, John
    Zaher, Atef
    Szatrowski, Ted
    Zhou, Wei
    Gjyrezi, Ada
    Tasaki, Shinsuke
    Portella, Luigi
    Bai, Yang
    Lannin, Timothy B.
    Suri, Shalu
    Gruber, Conor N.
    Pratt, Erica D.
    Kirby, Brian J.
    Eisenberger, Mario A.
    Nanus, David M.
    Saad, Fred
    Giannakakou, Paraskevi
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (28) : 3181 - +
  • [4] Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial
    Baciarello, Giulia
    Delva, Remy
    Gravis, Gwenaelle
    Tazi, Youssef
    Beuzeboc, Philippe
    Gross-Goupil, Marine
    Bompas, Emmanuelle
    Joly, Florence
    Greilsamer, Charlotte
    Hon, Thierry Nguyen Tan
    Barthelemy, Philippe
    Culine, Stephane
    Berdah, Jean Francois
    Deblock, Mathilde
    Ratta, Raffaele
    Flechon, Aude
    Cheneau, Caroline
    Maillard, Aline
    Martineau, Geraldine
    Borget, Isabelle
    Fizazi, Karim
    EUROPEAN UROLOGY, 2022, 81 (03) : 234 - 240
  • [5] A multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): CHEIRON study.
    Caffo, Orazio
    Palesandro, Erica
    Nole, Franco
    Gasparro, Donatello
    Mucciarini, Claudia
    Aieta, Michele
    Zagonel, Vittorina
    Iacovelli, Roberto
    De Giorgi, Ugo
    Rossetti, Sabrina
    Fratino, Lucia
    Sacco, Cosimo
    Nicodemo, Maurizio
    Giordano, Monica
    Sartori, Donata
    Scapoli, Daniela
    Verri, Elena
    Kinspergher, Stefania
    Pappagallo, Giovanni L.
    Aglietta, Massimo
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [6] Management of Metastatic Castration-resistant Prostate Cancer (mCRPC) After an Initial Good Response to First-line Docetaxel (D) - a Retrospective Study on 270 Patients (pts)
    Oudard, S.
    Kramer, G.
    Creppy, L.
    Loriot, Y.
    Steinbjoern, H.
    Holmberg, M.
    Rolland, F.
    Machiels, J. P.
    Krainer, M.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S499 - S500
  • [7] Baseline analysis of circulating tumor cell (CTC) enumeration and androgen receptor (AR) localization in men with metastatic castration-resistant prostate cancer (mCRPC) in TAXYNERGY.
    Tagawa, Scott T.
    Galletti, Giuseppe
    Antonarakis, Emmanuel S.
    Tasaki, Shinsuke
    Gjyrezi, Ada
    Worroll, Daniel
    Portella, Luigi
    Kirby, Brian J.
    Stewart, John
    Zaher, Atef
    Saad, Fred
    Vanhuyse, Marie
    Suri, Shalu
    Lannin, Timothy B.
    Gruber, Conor
    Pratt, Erica
    Sonpavde, Guru
    Eisenberger, Mario A.
    Nanus, David M.
    Giannakakou, Paraskevi
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [8] Circulating tumor cell (CTC) rise and outcome in patients with metastatic castration-resistant prostate cancer (mCRPC) with low baseline CTC counts.
    Lorente, David
    Olmos, David
    Mateo, Joaquin
    Zafeiriou, Zafeiris
    Rescigno, Pasquale
    Bianchini, Diletta
    Mehra, Niven
    Molina, Arturo
    Kheoh, Thian
    Baeten, Kurt
    Mccormack, Robert Thomas
    Terstappen, Leon W. M. M.
    Scher, Howard I.
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [9] First-line use of cabazitaxel in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC): A three-arm study in comparison with docetaxel
    Oudard, Stephane
    Sengelov, Lisa
    Mainwaring, Paul N.
    Thiery-Vuillemin, Antoine
    Theodore, Christine
    Kulikov, Evgeny
    Yachnin, Jeffrey
    Kocak, Ivo
    Kataja, Vesa V.
    Luukkaa, Marjaana
    Nosov, Aleander
    Hjelm-Eriksson, Marie
    Bubis, Jeffrey
    Shen, Liji
    Risse, Marie-Laure
    Sartor, A. Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients
    Lozano, Rebeca
    Lorente, David
    Aragon, Isabel M.
    Romero-Laorden, Nuria
    Nombela, Paz
    Mateo, Joaquim
    Reid, Alison H. M.
    Cendon, Ylenia
    Bianchini, Diletta
    Llacer, Casilda
    Sandhu, Shahneen K.
    Sharp, Adam
    Rescigno, Pasquale
    Garces, Teresa
    Pacheco, Maria I.
    Flohr, Penelope
    Massard, Christophe
    Lopez-Casas, Pedro P.
    Castro, Elena
    de Bono, Johann S.
    Olmos, David
    CANCERS, 2021, 13 (10)
12345